Showing 1 - 20 results of 15,519 for search '(( ct ((values decrease) OR (larger decrease)) ) OR ( 5 ((non decrease) OR (_ decrease)) ))', query time: 0.60s Refine Results
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7

    GO analysis of genes with decreased expression (<0.5) in <i>pab2</i>Δ. by Ziyue Liu (381532)

    Published 2025
    “…<p>GO analysis of genes with decreased expression (<0.5) in <i>pab2</i>Δ.</p>…”
  8. 8
  9. 9
  10. 10

    Inhibition of NEAT1 decreased the miR-204-5p expression and increased Six1 expression. by Lei Li (29537)

    Published 2024
    “…<p>(A) NEAT1 expression following siRNA transfection in BEAS-2B cells; (B-D) The expression of NEAT1, miR-204-5p, and Six1 after decreasing NEAT1 expression. * p <0.05, *** p < 0.001, and **** p <0.0001.…”
  11. 11

    Validation of genetic markers for risk of OA or knee OA for decrease in minJSW. by Mieke L. M. Bentvelzen (21594442)

    Published 2025
    “…<p><b>(A)</b> Manhattan plot of minJSW decrease at 24 months. The Manhattan plots show the -log10(P) values of all ~ 1,5 million SNPs against their position. …”
  12. 12

    Image 5_Exploration of the diagnostic and prognostic roles of decreased autoantibodies in lung cancer.tif by Ying Ye (72583)

    Published 2025
    “…</p>Methods<p>In this study, we applied the HuProt array and the bioinformatics analysis to assess the diagnostic values of the decreased autoantibodies in lung cancers.…”
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17

    Nineteen SNPs with significant association (<i>P < </i>5 × 10<sup>−8</sup>) with risk on minJSW decrease in knee OA. by Mieke L. M. Bentvelzen (21594442)

    Published 2025
    “…<p>Nineteen SNPs with significant association (<i>P < </i>5 × 10<sup>−8</sup>) with risk on minJSW decrease in knee OA.…”
  18. 18
  19. 19

    Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc by Lei Wang (6656)

    Published 2025
    “…The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …”
  20. 20